The University of Southampton
University of Southampton Institutional Repository

Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice

Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice
Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice

Immune checkpoint inhibitors targeting PD-1 or PD-L1 represent a standard treatment option for patients with advanced non-small-cell lung cancer. However, a substantial proportion of patients will not benefit from these treatments, and robust biomarkers are required to help clinicians select patients who are most likely to benefit. Here, we discuss the available evidence on the utility of clinical characteristics in the selection of patients with advanced non-small-cell lung cancer as potential candidates for single-agent anti-PD-1/PD-L1 therapy, and provide practical guidance to clinicians on identifying those patients who are most likely to benefit. Recommendations on the use of immune checkpoint inhibitor in clinically challenging populations are also provided.

atezolizumab, immune checkpoint blockade, nivolumab, non-small-cell lung cancer, patient selection, pembrolizumab
1479-6694
2415-2431
Califano, Raffaele
64302730-441a-494f-a1f4-d1a32f40b1cb
Lal, Rohit
87e5f1bc-7751-4d74-8c3f-ae8eb54dee44
Lewanski, Conrad
81511a8b-bedc-412e-aecd-0f576069337e
Nicolson, Marianne C.
0c77c193-777f-4701-bbb5-e3c27607aebb
Ottensmeier, Christian H.
42b8a398-baac-4843-a3d6-056225675797
Popat, Sanjay
10c354ba-52df-4cc8-8f46-7994dc241a0a
Hodgson, Matthew
73990390-889d-48e1-a54c-131c205fc981
Postmus, Pieter E.
9466b1e0-27e5-4d9d-965d-ed225c162c04
Califano, Raffaele
64302730-441a-494f-a1f4-d1a32f40b1cb
Lal, Rohit
87e5f1bc-7751-4d74-8c3f-ae8eb54dee44
Lewanski, Conrad
81511a8b-bedc-412e-aecd-0f576069337e
Nicolson, Marianne C.
0c77c193-777f-4701-bbb5-e3c27607aebb
Ottensmeier, Christian H.
42b8a398-baac-4843-a3d6-056225675797
Popat, Sanjay
10c354ba-52df-4cc8-8f46-7994dc241a0a
Hodgson, Matthew
73990390-889d-48e1-a54c-131c205fc981
Postmus, Pieter E.
9466b1e0-27e5-4d9d-965d-ed225c162c04

Califano, Raffaele, Lal, Rohit, Lewanski, Conrad, Nicolson, Marianne C., Ottensmeier, Christian H., Popat, Sanjay, Hodgson, Matthew and Postmus, Pieter E. (2018) Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice. Future Oncology, 14 (23), 2415-2431. (doi:10.2217/fon-2018-0330).

Record type: Review

Abstract

Immune checkpoint inhibitors targeting PD-1 or PD-L1 represent a standard treatment option for patients with advanced non-small-cell lung cancer. However, a substantial proportion of patients will not benefit from these treatments, and robust biomarkers are required to help clinicians select patients who are most likely to benefit. Here, we discuss the available evidence on the utility of clinical characteristics in the selection of patients with advanced non-small-cell lung cancer as potential candidates for single-agent anti-PD-1/PD-L1 therapy, and provide practical guidance to clinicians on identifying those patients who are most likely to benefit. Recommendations on the use of immune checkpoint inhibitor in clinically challenging populations are also provided.

Text
fon-2018-0330 - Version of Record
Download (1MB)

More information

Accepted/In Press date: 11 June 2018
e-pub ahead of print date: 6 July 2018
Published date: 1 October 2018
Keywords: atezolizumab, immune checkpoint blockade, nivolumab, non-small-cell lung cancer, patient selection, pembrolizumab

Identifiers

Local EPrints ID: 423863
URI: http://eprints.soton.ac.uk/id/eprint/423863
ISSN: 1479-6694
PURE UUID: 2d0a794a-80d2-4b50-b127-7316243c5850

Catalogue record

Date deposited: 03 Oct 2018 16:30
Last modified: 16 Dec 2019 17:57

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×